PAHC
Phibro Animal Health Corporation · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -10.0% ·
share flow +8.9% ·
net new positions -11.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 6.87K | $256,897 | +1 | n/a |
| Q2 2026 | 75 | -15 | 15.40M | $484.24M | +5 | −22 |
| Q1 2026 | 95 | +6 | 14.51M | $800.97M | +11 | −5 |
| Q4 2025 | 89 | +1 | 14.47M | $540.64M | +1 | n/a |
| Q3 2025 | 17 | +1 | 9.22M | $372.92M | +1 | n/a |
| Q2 2025 | 13 | +1 | 8.13M | $207.65M | +2 | −1 |
| Q1 2025 | 9 | 0 | 3.02M | $64.46M | +1 | −1 |
| Q4 2024 | 9 | -1 | 3.00M | $62.94M | n/a | −1 |
| Q3 2024 | 9 | -1 | 1.81M | $40.65M | n/a | −1 |
| Q2 2024 | 10 | n/a | 1.66M | $27.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 946.83K | n/a | $19.88M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 557.80K | +1.9% | $11.71M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 515.98K | +1.7% | $10.84M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | AQR Capital Management ✦ | 327.42K | +27.8% | $6.88M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 5 | Arrowstreet Capital ✦ | 322.09K | +35.6% | $6.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 207.75K | +233.0% | $4.36M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 82.00K | -7.2% | $1.72M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 8 | D. E. Shaw & Co. ✦ | 19.29K | -74.9% | $405,006 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 17.67K | +9.7% | $372,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $290,621 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 255 holders, 20.06M shares, $1.03B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
48.2% of class · View original SEC filing ↗